A number of epidemiologic and clinical studies that have examined the relationship between erectile dysfunction, depression and cardiovascular disease are reviewed. Hypothetical mechanisms that can explain the correlations observed among these phenomena are described and a mutually reinforcing predictive model is proposed.
Introduction
Screening patients for erectile dysfunction (ED) will yield a high correlation to the presence of other medical conditions such as depression and cardiovascular disease. There is an interesting, understudied mutually reinforcing relationship between ED, cardiovascular disease and depression. 1 ± 3 It is the purpose of this paper to examine the various associations among these three conditions using population-based, epidemiologic studies where possible. The overall goal is to identify whether these three medical conditions share mutually reinforcing associations and predictors.
Depressive symptoms and cardiovascular disease
Several large-scale epidemiologic studies conducted within the last two decades have demonstrated that there is an association between the prevalence of depression and cardiovascular disease. Carney et al studied 52 patients with coronary artery disease and found the prevalence of major depression to be 18%. 4 In 283 patients who had suffered a myocardial infarction (MI), Schleiffer et al found the prevalence of depression to be approximately 18%. 5 Likewise, 16% of 222 post-MI patients were found by Frasure-Smith et al to encounter serious depression. 6 Finally, Gonzalez et al reported the prevalence of depression to be 23% in a sample of patients with advanced coronary artery disease. 7 In patients with coronary artery disease, depression predicts future adverse cardiac events and hastens mortality. Several investigations have attempted to assess the risk of cardiovascular morbidity and mortality in patients with depressive symptoms. In a series with 1003 patients, 8 Murphy et al found the relative risk of depression for cardiovascular disease-related death was 2.50 for males and 1.50 for females. In a similar study of over 5000 patients, 9 Aromaa et al reported the relative risk of depression for cardiovascular disease-related death for males was 2.62 and for females was 1.90, in agreement with the ®ndings of Pratt et al, who estimated the relative risk of major depression for MI-related death to be 4.54 in 1551 patients. 10 Depression was identi®ed by Frasure-Smith et al as a signi®cant predictor of mortality (P`0.001) in 222 patients 6 months after MI, even after controlling for the effects of left ventricular dysfunction and a history of previous MI. 11 As early as 1979, in a large Danish study, Weeke et al reported a 50% increase in deaths from cardiovascular disease in depressed patients compared to the general Danish population. 12 In contrast, Weeke et al reported a lower risk of mortality from cardiovascular disease in depressed patients before and after antidepressant drug treatments. 13 After controlling for smoking, weight, activity, blood pressure and cholesterol, Glassman et al found that healthy individuals with depression were signi®-cantly more likely to develop and die of ischemic heart disease. 14 Depressive symptoms have also been associated with an overall increase in medical co-morbidity. Depressed patients experience increased medical complications, in part, because of de®cits in problem solving, coping with challenges, and poor compliance with medical therapy and rehabilitation. 15 Depression has been shown to precede the onset of coronary artery disease in individuals initially free of disease and there is also a greater risk of death in post-MI patients with depression, 16 but what are the mechanisms by which depression affects the cardiovascular and thrombotic systems? One hypothetical mechanism linking atherosclerosis to depression and heart disease is as follows. 16 Mental stress leads to dysregulation of the hypothalamic-pituitary-adrenocortical axis and sympatho-adrenal system via changes in corticotropin releasing factor, ACTH, endorphin and catecholamines. This dysregulation results in ventricular instability, myocardial ischemia, decreased or variability in heart rate and altered platelet receptors and reactivity. Any or all of these factors can precipitate atherosclerotic occlusive vascular disease, cardiac and cerebrovascular disease.
Erectile dysfunction and cardiovascular disease
Based upon recent epidemiologic studies, new estimates of the worldwide prevalence of ED have been developed. The estimates are conservative and predicated on the following: (i) United Nations data utilizing assumptions about future trends in fertility, mortality and migration which, for study purposes, were biased to the lowest projected values of these trends, and (ii) prevalence estimates were corrected for the more severe levels of ED, ie only those individuals with moderate to complete impotence were considered. Based upon these assumptions, the present worldwide prevalence of over 150 million men with ED is likely to more than double in the next 25 y, and will exceed 300 million men by 2025. The largest increase in new cases is projected to occur in Asia. 17 Findings from the Massachusetts Male Aging Study (MMAS) 18 have shown that the physiologic correlates of ED include age, diabetes mellitus, treated heart disease, treated high blood pressure, other cardiovascular medications, sedentary behavior and low serum DHEAS. Increased understanding of the links between ED and cardiovascular risk factors for ED may reveal important potential targets for intervention. Vascular risk factors, such as diabetes, heart disease, hypertension, low HDL, cigarette smoking, peripheral vascular disease and cerebrovascular disease have all been implicated in the etiology of ED. Other risk factors such as obesity, sedentary behavior and chronic alcoholism have also been implicated in some studies.
More recent epidemiologic studies have investigated such concepts as`alterations in risk factor exposure' and`risk of developing new-onset ED' in large community samples. These studies allow for longitudinal assessment of relevant risk factors. Utilizing follow-up data from the MMAS, 18 an investigation of initially potent or mildly impotent men was undertaken to determine whether changes in cigarette smoking, heavy drinking, sedentary lifestyle and obesity were associated with an increased risk of developing moderateasevere ED. Men had been followed for an average of 8 y. Results revealed a low risk of ED among men who maintained a physical activity level of at least 200 kcal per day. In addition, the ED risk was high among men who exhibited sedentary activity levels at both baseline and follow-up. Most importantly, the risk of ED was signi®cantly reduced among men who were sedentary at baseline and became physically active during the course of the study. Although few studies have assessed the impact of physical activity on ED, this study provides one additional link between ED and cardiovascular disease. One other study reported enhanced sexual function among men who participated in a randomized trial of aerobic exercise. 19 The association between cardiovascular disease and ED may be related to increased catecholamine loading during sexual performance, especially in patients with ED. Factors such as fear of failure, performance anxiety, anger, shame and embarrassment may lead to release of systemic norepinephrine. Catecholamine loading during sexual performance may be related to physiologic and psychologically-mediated sexual related pain, such as Peyronie's disease, prostatitis, epididymitis or non-genital pain (eg headache). Finally, a physiologically-induced catecholamine load may be related to sexual performance itself. At the time of orgasm, there is a mean energy expenditure of 3 ± 5 metabolic equivalents (METS). During sexual performance, the heart rate increases from 50 ± 60 beats per minute to a value approaching 120 beats per minute. 20 Similarly, the systolic blood pressure increases from the normal value of 120 mm Hg to approaching 170 mm Hg. In summary, sexual activity involves catecholamine loading and cardiovascular activation 21 that may be associated with ED in some patients.
Depressive symptoms and erectile dysfunction
Previous investigations of the association between ED and depressive symptoms have suffered from a lack of adequate assessment, poor sampling techniques, and inconsistent measurement of the exhibited symptoms. In contrast, the MMAS was a prospective epidemiological study in a randomly selected sample of 1709 men aged 40 ± 70 in 11 citiesatowns in the greater Boston metropolitan area. 2, 24 The overall study response rate was 53%, comparable to other epidemiological ®eld studies involving phlebotomy and a restricted time window for evaluation due to fasting or morning blood sampling. The population studied was consistent with the Massachusetts population in 1990 (US Census). Communities were randomly selected for Screening for erectile dysfunction I Goldstein inclusion by the use of probabilities proportional to the population within six strata de®ned by size and median income. The sampling fractions were adjusted to produce age distributions uniform across three decades, between 40 and 70 y. 2 The presence or absence of depressive symptoms was characterized by the Center for Epidemiologic Studies Depression Scale (CES-D) inventory. A score equaling or exceeding 16 of 32 total points was consistent with the presence of depressive symptoms. The instrument does not indicate a diagnosis of clinical depression, but it does discriminate between clinically depressed patients and nondepressed individuals. Further, the instrument correlates highly with more extensive scales designed to measure depression. 2, 24 The primary objectives of this study were to determine whether ED was systematically associated with depressive symptoms and to determine if the association was independent of aging and para-aging factors (factors highly correlated with aging) such as physical health, medications, education, hormones and activity levels.
The presence or absence of`moderate' or`complete' ED was characterized in the following fashion. Each subject was given a self-administered questionnaire on sexual activity for completion in private. Nine items were directly related to erectile potency and responses to these nine items were linked to a direct assessment of ED (none, minimal, moderate or complete) by means of a separate calibration study. 24 Only those subjects with moderate or complete ED were utilized in the substudy analysis of the association between ED and depression.
All analyses were performed on the ®xed sample of 1265 men (which represented 74% of the total 1709 men in the MMAS study) who had no missing data for both ED (moderate and complete) and depressive symptoms (CES-D b 16a32) as primary variables. The prevalence of each primary variable were expressed in 5-year age intervals. The prevalence of ED nearly doubled with aging. At age 40 ± 44 y, the prevalence was 25%. At age 65 y and above, the prevalence was 47%. In contrast, the prevalence of depressive symptoms was relatively constant at approximately 12% across age groups.
However, when correlations were performed within speci®c age cohorts (eg 40 ± 50; 51 ± 60; and 61 ± 70 y), a strong positive association was found between ED and depressive symptoms. Further, if depressive symptoms were divided by quintiles, the upper quintiles of depressive symptoms were associated with signi®cantly higher rates of ED, independent of age. Based upon logistic regression analyses, depressive symptoms were found to be a strong predictor of ED. Speci®cally, the odds ratio (OR) for the association of ED with depressive symptoms was 2.03 (95% CI 1.39 ± 2.96).
The association was consistent across strata of age, medical conditions, and physical activity. Additional ORs for the association of ED with depressive symptoms for treated heart disease was 2.30 (0.46 ± 11.4), for untreated heart disease was 1.42 (0.38 ± 5.20), for treated diabetes mellitus was 2.48 (0.45 ± 13.7), for untreated diabetes mellitus was 7.38 (0.79 ± 69.4), and for physical activitỳ 200 kcaladay was 1.25 (0.66 ± 2.38). Finally, multiple regression analyses were conducted on the complete list of potential predictors of the association between ED and depressive symptoms. Depressive symptoms, which were a strong predictor of ED in simple regression analysis, remained a strong predictor of ED when other potential predictors in the multiple regression analysis were controlled for. Independent of all confounders, moderate to complete ED was 1.82 times more likely in those who exhibited depressive symptoms compared with those who did not exhibit depressive symptoms.
A more recent study prospectively evaluated the effects of drug therapy for ED with sildena®l on comborbid symptoms of depression. Speci®cally, a randomized double-blind safety and ef®cacy study was performed involving a¯exible dose (25 ± 100 mg) of sildena®l versus placebo during 12 weeks of treatment in approximately 150 men with ED and untreated co-morbid depressive symptoms [Hamilton Depression Rating Scale (HAM-D) b 12a24]. 22, 23 After three months of treatment, a large majority (83%) of sildena®l patients were considered by strict criteria to be ED treatment responders. ED treatment responders showed a highly signi®cant decrease in multiple measures of depressive mood, while non-responders (regardless of drug vs placebo assignment) showed no improvement in depressive symptoms. A causal relationship between ED and depressive symptoms was strongly implied by these ®ndings. 22, 23 Previous models which accounted for an association of ED and depressive symptoms utilized à behavior-based' model. 24 According to such models, depressed individuals exhibit self-focus and spectatoring behaviors which lead to performance anxiety and subsequent ED. Alternatively, thè biologic-based' model has been proposed, 25 in which depressed individuals are viewed as exhibiting overactivity of the autonomic nervous system. This overactive autonomic sympathetic activity leads to an inability to initiate or maintain relaxation of the corporal smooth muscle tissue by inducing heightened adrenergic tone in the erectile tissue. 25 
A new two-way model
Data from the MMAS suggests a new integrated model to account for the association of ED and Screening for erectile dysfunction I Goldstein S149 depressive symptoms. In this new model, a two-way mutually reinforcing relationship is postulated to exist between the primary variables. One is unable a priori to determine which variable takes precedence, or is etiologically antecedent. Is it the ED which leads to depressive symptoms, or the depression which leads to ED? Erectile dif®culties may cause or exacerbate depressive symptomatology, which may, in turn, cause or exacerbate ED.
Both ED and depressive symptoms exhibit multifactorial etiologies, including organic and nonorganic components. The newly proposed mutually reinforcing model accounts for the erection problem being expressed in terms of the subjective experience of the patient's dysfunction, and is not limited to the mechanical inability to achieve or maintain an erection. The new model also considers the relationship of the patient with ED to his social milieu. In this sense, ED is a process of subjective evaluation of the individual's erection, and exists when a man's perception is that his erections are not suf®ciently rigid for satisfactory intercourse, whether this includes coitus or not. In the`new' model, ED may lead to a decline in both mental and physical health, and may in¯uence or be in¯uenced by a wide range of aging and para-aging phenomena. 26 The triad of depressive disease, cardiovascular symptoms and erectile dysfunction: a mutually reinforcing model In the proposed model, a three-way holistic, mutually reinforcing relationship between depressive symptoms, cardiovascular disease and ED is postulated, based on the repeated observation that the frequently observed conditions of depressive illness, cardiovascular disease and ED share many of the same risk factors and etiological associations. 26 One important consequence of this model is that patients presenting with symptoms of ED should be routinely screened for symptoms of depression and cardiovascular disease. Likewise, patients who present with depressive symptoms should be evaluated for both ED and cardiovascular disease. Finally, and of particular relevance to the screening for ED, clinicians involved in the management of sexual dysfunction should pay special attention to the likely co-morbidity of cardiovascular disease and depression, as well as the potential increased risk for cardiac morbidity and mortality in these patients.
Dr Moreland: In your ®rst presentation, you talked about depression, cardiovascular disease and impotence. In the second talk you also mentioned intimacy, desire, arousal, and female sexual dysfunction. With all of these psychosocial interactions and with us being very peripherally and smooth muscle oriented researchers and clinicians, how do you strike a balance between the psychosocial and the peripheral and practice-oriented? Dr Goldstein: It's a complicated ®eld, sex. It's not just a penis and it's not just a clitoris or a vagina. One has to keep perspective when one does research in here. Putting in an implant doesn't solve the problem. Using Viagra sometimes doesn't solve the problem. We have to be broader, especially when you start investigating women. Because you see the couple in some situations, both with their dysfunctions. You hear how the women speaks of the male's functions and how the men speak of female functions. We have to broaden ourselves and incorporate female sexual dysfunction in our evaluations. The uni-gender approach will disappear one day.
Dr Melman: With the advent of HMO's, we're changing the health care system and it makes it almost impossible to practice that kind of medicine. We have a dilemma that the best medicine is very dif®cult to deliver because of the increasing number of patients and the decreased duration of time we have to take care of them.
Dr Lewis: Tap Pharmaceutical has recently done a series of interviews and we're just starting to get the data. We ®rst took the patients who had erectile dysfunction and, of course, their main concern was that they were having a problem with erection. We next followed up with the wives and their concern was not with a lack of erectile function, rather, it was how it affected their husband's total personality. Their overwhelming major concern is one we really haven't addressed yet. Studies like this are going to begin to get at the root of how we should interact with the couple.
